https://www.selleckchem.com/products/sr-18292.html
Thus, SLAMF3 may be a novel immunotherapeutic target in MM. SLAMF2 and SLAMF6 are also expressed strongly on MM cells, and the safety of antibody-drug conjugates that target these molecules in patients with RRMM is currently under study. Our and others' reports demonstrate the value of SLAMF molecules as promising new targets for antimyeloma immunotherapies.Von Willebrand disease (VWD) is among the most common inherited bleeding disorders. Interestingly, acquired von Willebrand syndrome (AVWS) is diagnosed much less frequently, but can
Like
Comment
Share
